Breast cancer is the third most frequent cancer in the world as it affects approximately one in ten women in the western world[@b1]. The initial knowledge that connected breast cancer to genetic susceptibility originated from the clinical observations that highlighted the clustering of breast cancer cases in families[@b2][@b3]. Approximately 5--10% of breast cancers are believed to result from the inheritance of rare genetic components that confer significantly elevated risk[@b4][@b5]. For example, mutations in the tumor suppressor genes *BRCA1* and *BRCA2* account for approximately 16% of the familial breast cancer[@b6][@b7][@b8]. The vast majority of breast cancer cases, however, are derived from a complex interaction between multiple environmental, lifestyle and genetic factors with relatively weak individual risk contribution[@b9][@b10].

While the effects of many environmental and lifestyle factors, such as diet, reproductive behavior and radiation are well appreciated, the knowledge on genetically contributing patterns is limited. Association studies have identified *ATM, BRIP1*, *CASP8, CDH1*, *CHEK2*, *PALB2*, *PTEN*, *STK11*, and *TP53* as breast cancer susceptibility genes. Such mutations collectively account for 2.3% of familial risk of breast cancer, and together with *BRCA1*, *BRCA2* and others have been implicated in high risk screening strategies[@b5][@b8][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20]. Nonetheless, significant proportion of the familial and non-familial breast cancer susceptibility remains unknown, suggesting plethora of genetic elements that need to be understood.

Transcriptome sequencing comprises a unique interplay between individual genetic background, reflected in the variation content, and the epigenetic and environmental regulation affecting gene expression levels and splice patterns. Recent transcriptome sequencing efforts have highlighted important somatic events in metastatic triple negative breast cancer (TNBC) and described important for the clinical outcome genotype-phenotype correlations[@b21]. Further, transcriptome sequencing data have been successfully explored to reveal disrupted pathways in TNBC through genome-wide loss of heterozygosity and mono-allelic expression estimation[@b22]. As a result of these and other studies, the feasibility of transcriptome sequencing to uncover molecular mechanisms of breast cancer drivers is increasingly appreciated[@b23].

Here we used whole transcriptome RNA-sequencing to reveal the variation signatures of 17 breast cancer patient tissues, and compared with human normal breast organoids (referred from here on as normal breast tissue, NBT). The 17 samples include six TNBC, lacking expression of therapeutically significant components - estrogen receptor (ER), progesterone-receptor (PR) and the Human Epidermal Growth Factor Receptor 2 (HER2); six Non-TNBC (ER, PR and HER2-positive); and five HER2-positive samples (ER and PR negative). Compared to the extensively performed searches for somatic breast cancer mutations, our RNA-sequencing based approach detects SNPs that are expressed at the mRNA level, and allows estimation of their allelic expression at nucleotide resolution. A set of novel variants were validated through Sanger sequencing. As a proof-of-principle, we have explored the effect of a rare SNP- p.R353Q - in the epithelial splicing regulatory protein ESRP2, on the binding and splicing of its target pre-mRNA. Our study reports a set of novel mutations in essential regulatory molecules in breast cancer and discusses their allelic preferential expression and potential involvement in breast cancer.

Results
=======

Analytical strategies and overall variation landscape
-----------------------------------------------------

We set out to define the transcribed variation profile of TNBC, Non-TNBC and HER2-positive breast cancer samples. To achieve this, we applied mRNA sequencing on 17 breast cancer samples from unrelated individuals as well as on three NBT samples on the Illumina HiSeq 2000 platform. The raw reads were aligned against Ensembl GRCh37.62 B (hg19) using TopHat[@b24], and the variants were called using Samtools[@b25]. Prior to filtering, a total of 1,876,617 SNPs, 331,197 of which were novel, were called across all 17 breast cancer samples, and between 30,294 and 258,465 SNPs (average 110,389) were called in each individual sample ([Supplementary Table 1](#s1){ref-type="supplementary-material"}). The overview of the workflow and the filtering strategy is presented in [Figure 1](#f1){ref-type="fig"}. The SNP calls were separated into two groups -- either reported in the databases (between 22,914 and 218,411 per sample, average 91,201), or novel. The previously reported SNPs, due to validation by at-least one independent group, were analyzed further without filtering. To increase the confidence in the calls of novel variants, we initially analyzed the SNP calling reads of 1,000 SNPs through Integrative Genomics Viewer (IGV) files, and 96 of the calls were tested by Sanger sequencing. Based on the findings of this pilot validation test, we set up filtering criteria retaining minimum false-positive and false-negative calls as follows: those supported by at least of three bidirectional reads with unique start position, minimum phred quality value of 20, mapping quality value (MQV) \> 20, and presence in 3 or less different samples. To ensure that we were not missing any novel high prevalence SNPs among our samples, all the positions at which a novel SNP was called in 4 or more samples were visually examined through IGV before to be assigned as false positives -- no novel SNPs called in 4 or more samples were identified. This filtering left us with between 60 and 1143 novel variants per sample (average 285). The transition to transvertion (Ts/Tv) ratio among the novel coding SNPs was 2.8 and aligns with previously reported values for human exome, thus increasing the confidence of our filtering algorithm[@b26][@b27].

Prior to filtering, between 1,574 and 11,669 previously reported INDELs were called in each of the studied breast cancer samples and subjected to further analysis (See [Supplementary Table 1](#s1){ref-type="supplementary-material"}). The novel INDELs were quality filtered to remove calls with MQV less than 20, phred quality value below 20 and presence in three or more different samples. This left between 18 and 142 novel INDELs (average 59) per sample, which were retained in our further analysis.

Expressed SNP density
---------------------

To assess the overall expressed variation landscape of the breast cancer samples, we estimated the SNP density by counting the number of SNPs per megabase (MB) genome intervals. The SNP density was calculated individually for each sample and compiled per group (TNBC, non-TNBC and HER-2), and as a whole for the 17 samples ([Figure 2](#f2){ref-type="fig"}). Overall, the SNP density distribution across the three groups was very similar, with a few regions showing group-specific high-density loci. All the TNBC samples presented with high number of SNPs in the region of chr14:10500000--106000000, which was mainly contributed by increased overall SNP number in the large gene encoding nucleoprotein *AHNAK2*. Specifically enriched in all non-TNBC samples was the region on chr19:53000000, mainly due to high number of SNPs in the zinc finger protein (*ZNF*) encoding genes.

We also overlapped the expressed overall SNP density in our samples with somatic genome SNP density calculated from the COSMIC dataset. There was a significant overlap in the overall SNP distribution. However, the regions with highest SNP frequency differed: while in the COSMIC dataset they were chr2:48000000, chr17:20000000 and chr5:72000000, the three top SNP-enriched regions when all of our samples were analyzed together were chr6:31000000--32000000, chr8:144000000 and chr19:53000000. While the high density observed on chromosome 6 was due to a the well-known variability in the histone cluster (*HIST1H1A*) and major histocompatibility complex (*HLA*), the chromosome 8 region was enriched by variants in epidermal antigen Epiplakin1 (*EPPK1*) and lymphocyte antigen (*LY6E*) (see [Figure 2](#f2){ref-type="fig"}).

Comparative analysis with cancer genome variations (COSMIC)
-----------------------------------------------------------

We compared the SNPs identified in our samples with the COSMIC cancer genome somatic mutation database (<http://www.sanger.ac.uk/cosmic>)[@b28]. A total of 2,169 SNPs from the COSMIC database were found among our samples, 129 of which were present in more than 10 of the 17 samples, and 6 were called in all breast cancer samples. Only one SNP -- the relatively common variant R1322X in the ABC transporter gene *ABCA10* was nonsense, 515 were missense and 20 were located within a splice site. Of note, only two of the SNPs in our dataset, both UTR located, overlapped with COSMIC variants found in breast cancer: 1) the promoter T \> C substitution in the proto-oncogene binding Yes-associated protein (*YAP1*) was seen in 8 of our 17 patients, and 2) the 3′-UTR C \> T substitution in peptidylprolyl isomerase F (*PPIF*) was found in 5 of our samples. Among these comparisons, highly represented in our datasets were COSMIC missense variants in the DNA-repair encoding probable helicase senataxin *SETX* and Ewing\'s tumor-associated antigen *ETAA1*.

GWAS associated SNPs in the breast cancer transcriptome
-------------------------------------------------------

To outline SNPs that have been previously associated with breast cancer phenotypes, we overlaid our datasets with the publically available genome wide association studies (GWAS); the results are summarized in [Supplementary Table 2](#s1){ref-type="supplementary-material"}. The pre-B-cell leukemia homeobox 1 (*PBX1*) intronic SNP rs1387389 that has been reported to strongly associate with early onset breast cancer[@b29] was present in 4/17 samples, two of which were homozygous. Similarly, two breast cancer associated SNPs in the fibroblast growth factor receptor (*FGFR2*)[@b30], rs2420946 and rs2981582, were present each in two of our samples, (one patient was a carrier of both), again, in a homozygous state. Of note, the mitogen-activated protein kinase kinase kinase (*MAP3K1*) SNP reported by the same study was not present among our samples, however, we found a higher prevalence of the closely positioned D860N and V906I missense substitutions in *MAP3K1*; they were called in 13 (9 homozygous) and 16 (11 homozygous) of our samples, respectively. Similar high homozygocity prevalence was seen for the rs704010 rs8170, rs2180341, rs13281615, rs3817198 and rs4973768, but was not observed for the intergenic rs4415084. Other SNPs reported to be in strong association with breast cancer from recent meta-analyses[@b29][@b30][@b31][@b32][@b33] were not seen in our samples.

Variations in genes previously implicated in hereditary breast cancer
---------------------------------------------------------------------

To search for known predisposing breast cancer variants among our samples, we extracted SNPs and INDELS in genes that have been previously associated with hereditary breast cancer. Among all 17 samples, 80 SNP calls (38 unique SNPs) and 66 INDEL calls (38 unique INDELs) mapped within *ATM*, *BRCA1*, *BRCA2*, *BRIP1*, *CASP8*, *CDH1*, *CHEK1*, *PTEN*, *STK11* or *TP53*. While the majority of the SNPs called in those genes variants were common or have no known effect on the protein, several variants have been previously linked to breast cancer predisposition ([Table 1](#t1){ref-type="table"}). In *BRCA1* and *BRCA2* collectively, twelve different missense substitutions were identified in a total of nine patients. Five of the missense substitutions (p.Q356R, p.R496H, and p.D693N in *BRCA1*, and p.N289H and p.D1420Y in *BRCA2*) have been previously associated with breast cancer through either family or case-control studies[@b34][@b35]. Three patients from the non-TNBC group were carriers of the missense variant p.Q356R, and the other cancer-associated variants were present in one patient each -- from either non-TNBC or HER2 positive groups. The two *BRCA2* missense substitutions were seen in HER2-positive patients. In addition, one TNBC patient carried a small *BRCA1* deletion (chr17:41246251delC, rs80357794) that leads to a frame-shift and premature stop codon expected to completely abolish protein function. In the *ATM* gene, we identified the non-synonymous substitutions p.F858L and p.L1420F, which have been previously associated with increased risk for breast cancer[@b36]. The *ATM* missense p.F858L is known to impact the interaction of *ATM* with beta-adaptin, which is necessary for clatherin mediated receptor endocytosis and is proposed to contribute to the hereditary radio sensitivity and breast cancer[@b37][@b38]. In addition to breast cancer-associated variants, a missense substitution in *STK11*, p.H175Y, previously reported in a lung carcinoma[@b39] was been found in one patient. One non-TNBC patient carried simultaneously pathogenic variants in *BRCA1* and *ATM*. Of note, overall a higher number of variant versus reference reads was assessed across *BRCA1*, *BRCA2* and *ATM* variations.

Prevalence of rare variants
---------------------------

To reveal variants that might be overrepresented in our samples compared to the general population, we compared the allele frequency of coding SNPs called in our samples against 11,666 alleles from the Exome Sequencing Project dataset (<http://evs.gs.washington.edu/EVS/>). To minimize error due to different variant calling platforms and to increase the statistical significance of the findings, we excluded from this analysis SNPs called in less than 10 alleles from the ESP dataset and in less than 3 individuals among our 17 samples. SNPs called in all 17 of our samples were also excluded. For the purposes of allele frequencies comparison, we assigned two alleles for every homozygote call in our dataset; and Yates corrected chi-square was calculated for each distribution. The top 50 most prevalent missense SNPs among the 17 samples are presented in [Table 2](#t2){ref-type="table"}. The highest difference in the allele distribution between our dataset and ESP was estimated for rs2305376 in the gene *HOOK2*, encoding a component of the FTS/Hook/FHIP (FHF) complex that has a role in vesicle trafficking and maintenance of centrosome function and is known to interact with the *JUN* proto-oncogene[@b40][@b41]. Interestingly, the variant is predicted to be damaging change due to glycine to arginine substitution (p.G10R), which in addition to its low prevalence in the ESP datasets, is rare to absent in the European population datasets (see [Table 2](#t2){ref-type="table"}). This variant was called in 3 of our 17 samples, and all of them were called homozygous due to the high abundance of variant over wild type reads. Another overrepresented SNP in our dataset was the missense substitution p.T573A in the protein tyrosine phosphatase *PTPN12*, whose activity is lost in a large proportion of breast cancer cases[@b42]. Of note, while *PTPN12* loss is most strongly associated with the TNBC phenotype[@b43], we found this variant equally prevalent in all three breast cancer subtypes; one TNBC and one HER2-positive samples carried it in homozygote state. Other breast cancer implicated genes with prevalent variants amongst our samples were *PLEC*, *PRCP, DSG2* and *ERBB2IP*, all harboring predicted to be damaging aminoacid changes[@b44][@b45][@b46][@b47]. Potential contribution of such variants to the phenotype in these patients is worth investigation.

Deleterious protein mutations
-----------------------------

A selected subgroup of potentially deleterious SNPs consisted of mutations predicted to generate premature stop (PMS) codons through either nonsense substitution or a splice-site aberration leading to a frame-shift due to out-of-frame exon skip or intron retention. In this group we also retained SNPs removing a stop codon, because of their known severe biological consequences. A total of 1,593 variants of this type were called across our 17 samples, from which 77 were different nonsense SNPs and 16 were INDELs leading to a stop codon generation ([Table 3](#t3){ref-type="table"}). Among the stop-codon mutations, p.R93X in Steroid Receptor activator *SRA1* was present in 10 of the 17 samples, and in 8 of them it was called homozygous. Given that SRA1 is involved in regulating the activity of steroid receptors and is deregulated in breast cancer[@b48], the high expression rate of a nonsense variant might indicate functional implications in our breast cancer samples. In addition, two HER2 and two TNBC samples were positive for the p.Q281X in the zinc-activated ligand-gated ion channel (*ZACN*). Interestingly, the nucleotide change causing this mutation - chr17:74077797 C \> T - also resides in the 5′UTR of the gene encoding exocyst complex component (*EXOC7*), whose deregulated expression was reported to be a strong predictor for metastatic outcome in early stage TNBC[@b49]. The two TNBC samples positive for the variant did not show presence of reference reads in this position. When all the genes affected by a deleterious mutation were analyzed through Ingenuity Pathway Analysis (IPA), the top affected molecular networks were cell death and survival, cellular development, and cellular growth and proliferation, and the top affected canonical pathway was estrogen receptor signaling ([Supplementary Figure 1](#s1){ref-type="supplementary-material"}).

Novel expressed variations in breast cancer, and allele specific expression
---------------------------------------------------------------------------

The statistics on the filtered novel SNPs and INDELs are summarized in [Supplementary Table 3](#s1){ref-type="supplementary-material"}; a complete list of the novel exonic annotated variations is available upon request. As expected, majority novel variants mapped within gene regions (70% of the SNPs and 66% INDELs). Filtering out of the intronic calls significantly reduced both SNP and INDEL numbers to between 43 and 186 SNPs per sample (average 76) and between none and 17 INDELs (average 8). Overall, 8% of the novel intergenic SNPs and 4% of the novel INDELs mapped within exons. Across the 17 samples, the total number of genes with coding and regulatory sequences affected by at least one novel SNP was 2103, and the genes with at least one novel INDEL were 566. A selected set of exonic variants were confirmed by Sanger sequencing ([Figure 3](#f3){ref-type="fig"}).

From the novel exonic SNPs, 285 unique SNPs were predicted to alter the protein sequence. Based on position and function, three of these SNPs were annotated to generate a novel stop codon, 114 were located within 2 bp of a splice junction, and 174 were missense, from which 70 were predicted to significantly affect the protein function. Six novel SNPs had dual annotation: missense substitutions located at a splice site. A total of 121 novel coding SNPs affected highly conservative nucleotide positions. Three novel coding SNPs - one missense and two synonymous substitutions - were called in two samples, and one - a stop codon in the solute carrier *SLC30A8* (p.Q28X) - in three different breast cancer samples ([Table 4](#t4){ref-type="table"}). Interestingly, p.Q28X affects only one (NM_173851.2) of the five protein coding *SLC30A8* splice isoforms; this isoform possesses an alternative 5′-end and is present in all three samples from our set that expressed this isoform. The stop codon is located early in the protein chain and likely leads to complete abolishment of the protein expression. Since this *SLC30A8* isoform was not expressed in the remaining 14 breast cancer samples, this early stop codon may indicate regulatory mechanism preventing the expression of this particular isoform in breast tissue.

To assess potential allele preferential expression, we analyzed the ratio of reference and variant reads at all coding positions for the novel SNPs called by 6 or more reads harboring the variant nucleotide ([Figure 4](#f4){ref-type="fig"}). Fifty seven of these novel SNPs were called by variant reads only (i.e. no reference call was present at the corresponding position), and additional 53 showed higher than 5-fold number of variant calling reads over the wild type ([Supplementary Table 4](#s1){ref-type="supplementary-material"}). Among the most preferentially expressed novel SNPs were missense variants in previously linked breast cancer genes, such as methyl-thioadenosine phosphorylase *MTAP* (p.K71R), and melanoma antigen *MAGED1* (p.G87A)[@b50].

Studies revealing impaired interaction of splicing coordinator ESRP2 bearing a R353Q substitution
-------------------------------------------------------------------------------------------------

Among the novel and rare SNPs predicted to be protein-altering in our breast cancer samples, we selected to study the functional effect of the R353Q substitution in *ESRP2*, based on the established connection of ESRP2 to cancer through its role in epithelial-to-mesenchymal transition (EMT)[@b51][@b52][@b53]. Arginine 353 is located in the second RNA recognition motif (RRM) domain of the ESRP2, which is known to interact with specific pre-mRNAs sequences. There are three RRM domains in ESRP2, and they are implicated in regulating the expression of specific splice variants of *FGFR2*, *CTNND1* and *ENAH* that are involved in EMT. We applied site-directed mutagenesis to generate *ESRP2*^R353Q^ harboring expression vector and transfected MDA-MB-231 human breast cancer cells in parallel with expression constructs containing wild type *ESPR2*. After transfection, wild type and the mutant ESRP2^R353Q^ proteins were purified and compared for their ability to bind the *FGFR2* pre-mRNA region through Electrophoretic Mobility Shift Assay (EMSA); the results are shown in [Figure 5](#f5){ref-type="fig"}. We observed strong interactions between the wild type ESRP2 and the *FGFR2* pre-mRNA as previously reported[@b52]. However, this interaction was significantly impaired for the mutant ESRP2^R353Q^ (compare lanes 6 and 7 with Lanes 2 and 3, Panels A--C), suggesting that the R353Q substitution compromises ESPR2 binding, and potentially, splice regulation of the *FGFR2* pre-mRNA. This effect was observed in all three tested breast cancer cell lines: MCF-7 ([Figure 5A](#f5){ref-type="fig"}), MDA-MB-231 ([Figure 5B](#f5){ref-type="fig"}), and BT-549 ([Figure 5C](#f5){ref-type="fig"}). Further, in line with previous observations[@b52], RT-PCR showed increased expression of the epithelial FGFR2 isoform IIIb after transfection with wild type ESRP2 in the mesenchymal FGFR2 IIIc-expressing cell lines MDA-MB-231 and BT-549 ([Figure 5D](#f5){ref-type="fig"}). This increase in FGFR2 IIIb expression was lower (BT-549) to completely abolished (MDA-MB-231) after the transfection with the mutant ESRP2^R353Q^ ([Figure 5D](#f5){ref-type="fig"}).

Discussion
==========

Here we present the first mRNA sequencing based study that reports expressed variations in TNBC, Non-TNBC and HER2-positive breast cancer transcriptome. Several molecular mechanisms, such as RNA editing and allele preferential expression, could cause a discrepancy between the variations found at mRNA and DNA levels. Compared to exome and genome sequencing, RNA-seq provides essential insights into the functionality of the variants through estimation of the absolute and relative abundance of variant reads and the co-existence or mutual exclusion of variations, expression and splicing patterns. In addition to outlining the general landscape of the breast cancer variation transcriptome, our study reports novel variants in an allele-specific expression context, aligns our findings with the existing knowledge on breast cancer genetics, and exemplifies efficient extraction of information from the transcriptome through extensive analyses.

Mutations in previously associated breast cancer genes, *BRCA1*, *BRCA2* and *ATM*, were called in 9/17 (53%) samples which is a higher than the previously reported mutation prevalence among breast cancer patients[@b5][@b12][@b13][@b14][@b15][@b16][@b18][@b19][@b20]. While only one patient was a carrier of known pathological variants in both *BRCA1* and *ATM*, five other individuals carried missense substitutions in at least two different breast cancer associated genes (see [Table 1](#t1){ref-type="table"}). Whether the disease in these patients could be contributed to cumulative impaired functioning of these genes is a subject of further investigation; nevertheless, the relatively frequent co-occurrence of protein altering variations in known breast cancer-associated genes in different cancers raises the necessity to examine larger series of patients and controls for combinatorial genetic risk. An interesting observation is the high prevalence of homozygote vs. heterozygote calls in *BRCA1*, *BRCA2* and *ATM* for both breast cancer-associated genes, and those not known to be pathogenic variants, suggesting potential allelic loss in those genes.

Among the essential findings of our study is a subset of novel SNPs and INDELs, some affecting genes previously implicated in breast cancer, in which, however, no predisposing or causative point variants have been reported so far. An example is p.K71R in *MTAP*, frequently seen co-deleted with the *CDKN2A* and *CDKN2B* tumor suppressor genes in a large cohort of 2000 breast tumors[@b50]. While the biological significance of p.K71R in *MTAP* and other novel variations in cancer-associated genes is currently unclear, overexpression of novel variant over reference alleles points to a possible contribution to tumor initiation or progression. Since these variants have not been previously reported, they are not likely to be present in a homozygote state at the genomic level, and their allelic dominance may indicate expression or growth advantage, as well as potential loss of heterozygosity. Because such events may drive or contribute to cancer, a systematic investigation of allelic dominance of novel variants across larger expression sets is needed.

In addition, we also identified a higher frequency (compared to non-breast cancer populations) of previously reported variants in many genes, including breast cancer-associated genes, such as *PTPN12*, *PRCP*, *PLEC, DSG2* and *ERBB2IP*. Estimation of the prevalence of such variants in larger breast cancer cohorts is needed as it may indicate contribution to genetic risk or co-existence with causative mutations. Although this analysis holds promising potential to identify overrepresented alleles, it is important to take into account that transcriptome sequencing variant calls differs from the exome sequencing in allelic representation of homo- and heterozygote state (i.e. number of alleles). While homo vs. heterozygosity on transcriptome level provides an additional layer of information on the potential functionality of these variants, the results should be used only after confirmation by independent studies. Nevertheless, statistical confidence may be increased for SNPs in which the difference is achieved through the analysis of high number of samples rather than homozygote appearance, such as *PTPN12* and *DSG2* (see [Table 2](#t2){ref-type="table"}). Such prevalent variants in genes implicated in breast cancer are worthy of investigation in independent breast cancer datasets.

Similarly to the above discussed prevalence of mutant reads in breast cancer-associated variants, GWAS associated SNPs in our set also showed high prevalence of homozygous vs. heterozygous calls. This overall prevalence of variant over reference reads for variant positions in cancer implicated genes, needs to be further investigated as potential indicator of mechanistic implications, such as loss of heterozygosity or preferential allelic expression. As the information content of the transcriptome as a common denominator combining frequency and expression data is emerging, large scale studies are expected to enlighten the feasibility and the information value of these types of analyses[@b32].

Finally, we selected a rare, predicted to be protein damaging missense substitution from our dataset -- p.R353Q in the splicing coordinator *ESRP2* - to demonstrate *in vitro* the effect of the p.R353Q substitution on the *ESRP2* protein function. We were able to show that the replacement of the arginine 353 with the variant glutamine leads to a significant reduction of the binding ability of ESRP2 to *FGFR2* pre-mRNA. Thus, this could potentially affect epithelial-to-mesenchymal transition programs.

Overall, our analysis identified enrichment of variants known to be implicated in breast cancer as well as novel and rare variants in genes associated with breast cancer in our set of 17 breast cancer samples. Further, the within-individual exploration of the variance showed multiple disease associating variants in most of the individuals, and points to the need for estimation of cumulative action of genetic alterations. This study reports an initial collection of variants that are expressed across the breast cancer transcriptome, including novel and reported mutations in their allelic abundance and co-presence with other variants. In addition to providing an overall variation landscape of the breast cancer transcriptome, such as expressed SNP density and deleterious variants scaffold, we exemplify different analytical strategies to search for molecular interactions and regulatory networks potentially implicated in breast tumorigenesis. Compared to exome and genome studies, transcriptome exploration provides higher information content through the estimation of the expression abundance, in the immediate context of allelic prevalence and co-existence with expression and splicing features[@b54][@b55]. It is essential to keep in mind however that the transcriptome only captures a snap shot and further functional characterization of the observed molecular features is needed to prove disease-causative relationships. Nevertheless, our study provides an important breast cancer transcriptome dataset for further explorations on either high-throughput or individual gene/protein scale.

Methods
=======

Human patient samples
---------------------

The human breast cancer tissue RNA samples were provided by Dr. Suzanne Fuqua (Baylor College of Medicine). All of the human samples were used in accordance with the IRB procedures of Baylor College of Medicine and Dana-Farber Cancer Institute and Harvard Medical School, respectively. The breast tumor types, TNBC, Non-TNBC and HER2-positive, were classified on the basis of RNA sequencing FPKM abundance and immunohistochemical and qRT-PCR classification (data not shown) as previously described[@b54][@b55]. All breast cancer patients were from European descent.

Illumina genome sequencing RNA sequencing library preparation
-------------------------------------------------------------

Large and small ribosomal RNA (rRNA) was removed from total RNA using RiboMinus Eukaryote Kit (Invitrogen, Carlsbad, CA). Five micrograms of total RNA were hybridized to rRNA-specific biotin labeled probes at 70°C for 5 minutes. The rRNA-probe complexes were then removed by streptavidin-coated magnetic beads. The rRNA-free transcriptome RNA was concentrated by ethanol precipitation. The cDNA synthesis and DNA library construction for all the seventeen samples were performed as described[@b54][@b55].

Read alignment and transcript assembly
--------------------------------------

The paired end raw reads were aligned using the TopHat version 1.2.0 that allows two mismatches in the alignment. The aligned reads were assembled into transcripts using cufflinks version 2.0.0. The alignment quality and distribution of the reads were estimated using SAM tools. From the aligned reads, *de novo* transcript assembly was performed to capture the major splice rearrangements and novel variations that occur in the transcriptomes of TNBC, Non-TNBC and HER2- positive breast cancers in comparison to NBT using cufflinks version 1.3.036. The cuffcompare program was used to identify transcripts that are identical to the reference human genome (the Ensembl GRCh37.62 B (hg19) reference genome). Further analysis and novel isoform call was performed through the reconstructed transfrags that comprise novel splice junctions and share at least one splice junction with a reference transcript. The very low abundant transcripts were identified by binning the transcripts according to their FPKM and the transcripts with FPKM below 0.3 were eliminated from further analysis. All the analyses presented in this manuscript are performed using two categories of transcripts: transcripts that are identical to reference and transcripts that comprise novel junctions. The global statistics, which includes the distributions of FPKM scores across samples and the dendogram that shows the relationship between the samples based on the reconstructed transcripts, were analyzed using cummeRbund package of cufflinks suite of programs. The average exon number was in the reassembled transcripts is comparable to the human genome reference average. To annotate novel splice events, we used Multivariate Analysis of Transcript Splicing (MATS). Additionally, for consistency checking and independent validation we used an inhouse built program (<http://ccb.jhu.edu/software/ASprofile/>) to compare the exon models between isoforms assembled with the program cufflinks for the normal and cancer samples. As mentioned earlier, only the isoforms that are similar to reference and isoforms that comprise novel splice junctions were considered. We determined the splicing differences indicative of exon inclusion, exclusion, alternative 5′, 3′, and intron retention events.

Variants call and annotation
----------------------------

Variants calls were obtained using Mpileup utility of SAMTools (<http://samtools.sourceforge.net/mpileup.shtml>). Base Alignment Quality was used to score the variant call. Consensus calling is done using bcftools. Maximum depth call was set at 100000. The variants were annotated using SeattleSeq Annotation Tools version 8.01, dbSNP build 137 (<http://snp.gs.washington.edu/SeattleSeqAnnotation137/>).

Sanger sequencing
-----------------

First-strand cDNA was synthesized with SuperScript III reverse transcriptase (Invitrogen, Inc) using 1 μg of total RNA and mixture of oligo dT primer and random hexamers. For selected variants, cDNA primers flanking the variant position were designed using Primer3[@b56] and in RT-PCR to amplify the region of interest. The products were separated on 1% agarose gel, excited and purified using QIAquick Gel Extraction Kit (Qiagen, Inc.) according to the manufacturer instructions. The purified fragments were subjected to bi-directional Sanger sequencing with the forward and the reverse primer used for the amplification.

Statistics
----------

To test if the distribution of variant alleles differed between our group and non-breast cancer populations, we applied chi-square test (2 × 2 tables). All the values were subjected to Yates correction for contingency to prevent overestimation of significance; p values below 0.05 were considered significant.

EMSA
----

To determine if the R353Q substitution affects the ability of ESRP2 to bind its substrate we used wild type and mutant FLAG-tagged ESRP2 ORF introduced in PBIX as previously described[@b52]. Three cell lines MCF-7, MDA-231 and BT-549 were transfected cell lines using FuGENE® Transfection Reagents (Promega, Inc.) according to the manufacturer recommendations. Nuclear extracts were prepared using a Nonidet P-40 lysis method. RNA oligos of ISE/ISS-3 were end labeled with using the annealed \[γ-^32^P\] ATP in a 20 μl reaction mixture for 15 min at room temperature. RNA probes were incubated with respective nuclear extracts. Samples were run on a non-denaturing 6% polyacrylamide gel and imaged by autoradiography. Specific competitions were performed by adding a 100-molar excess of unlabeled probe to the incubation mixture and supershift Electrophoretic mobility shift assay (EMSA) were performed using FLAG antibody (Sigma-Aldrich).
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Different filtering strategies were applied to the novel and the previously reported variants. The previously reported variants, due to validation by at-least one independent group, were analyzed further without filtering. The filtering criteria for the novel variants were set as follows: those supported by a minimum of three bidirectional reads with unique start position, minimum phred quality value of 20, mapping quality value (MQV) \> 20, and presence in 3 or less different samples. All the positions at which a novel SNP was called in 4 or more samples were visually examined through IGV before assignment as false positives.](srep02256-f1){#f1}

![Expressed SNP density expressed as number of SNPs per megabase (MB) genome intervals.\
The SNP density was calculated individually for each sample and compiled per group (TNBC, non-TNBC and HER-2), and as a whole for the 17 samples. Overall, similar SNP density distribution is observed across the three groups. (A) Circos plot representing the high density expressed SNPs in TNBC, Non-TNBC and HER2 positive Breast Cancer Samples compared to cancer genome SNP data from COSMIC. (B) The highest SNP density loci for TNBC, Non-TNBC, HER2 and COSMIC, compared to the SNP density for the same locus for the other three groups. The highest SNP density for the COSMIC was observed in the interval chr2:48000000--48999999, containing the genes *MSH6*, *FBX011*, *FOXN2*, *PPP1R21*, *STON1*, *GTF2A1L* and *LHCGR*, while very low expressed SNP density for this region was measured in all three breast cancer subtypes.](srep02256-f2){#f2}

![Sanger Sequencing validation of selected variants; IGV is also presented.\
(A) *ESRP2*, p.R353Q; (B) *TPP1*, p.P320S; (C) *GBP1*, p.R244H; (D) *MAD2BP1*, p.R227X. For *TPP1*, *GBP1* and *MAD* both IGV and chromatogram show prevalence of the variant allele.](srep02256-f3){#f3}

![Allele preferentially expressed novel missense variants through estimation of the ratio of reference and variant reads.\
The Variant-to wild type allele ration was estimated for all the novel SNPs called by 6 or more reads harboring the variant nucleotide. Fifty seven novel SNPs were called by variant reads only (i.e. no reference call was present at the corresponding position), and additional 53 showed higher than 5-fold number of variant calling reads over the wild type. Among the most preferentially expressed novel SNPs were novel missense variants in previously linked to breast cancer genes such as methyl-thioadenosine phosphorylase *MTAP* (p.K71R), and melanoma antigen *MAGED1* (p.G87A).](srep02256-f4){#f4}

![EMSA of ESRP2 interaction with *FGFR2* ISE/ISS-3 cis-regulatory motif pre-RNA.\
The R353Q mutation in ESRP2 compromises FGFR2-IIIb expression. Vector (PIBX-CFF-B), ESRP2^wt^ or ESRP2^R353Q^ were transiently transfected in breast cancer cell lines: MCF-7 (A), MDA-MB-231 (B) and BT-549 (C). RNA binding of ESRP2^wt^ or ESRP2^R353Q^ is shown. The incubated samples were resolved on 6% native-PAGE gel and detected by Phosphor imager. D) R353Q mutation in ESRP2 compromises FGFR2-IIIb expression. Vector (PIBX-CFF-B), ESRP2-Wt or ESRP2-Mut (R353Q) were transiently transfected in mesenchymal breast cancer cell lines, MDA-MB-231 and BT-549. FGFR-IIIb was detected by RT-PCR. The bands were quantified and normalized by the actin band intensities.](srep02256-f5){#f5}

###### Variants in *ATM*, *BRCA1, BRCA2* and *STK11* identified in the 17 breast cancer samples (from HGMD, <http://www.hgmd.cf.ac.uk/ac/index.php>. The homo- or heterozygosity and the number of the unique variant and reference reads are also shown

  Gene       Chromosomal Location       cDNA         Protein      rsID     Function   Cancer Associated     ID     Cancer subtype     Zygosity     Var/ref calls
  --------- ---------------------- --------------- ----------- ---------- ---------- ------------------- -------- ---------------- -------------- ---------------
  *ATM*        chr11:108138003      c.2572 T \> C    p.F858L    1000056    missense          YES          IP2-71      Non-TNBC      heterozygote        3/2
               chr11:108160350      c.4258 C \> T   p.L1420F    1000058    missense          YES           171          HER2        heterozygote       9/10
               chr11:108175462      c.5557 G \> A   p.D1853N    1801516    missense          NO           IP2-42      Non-TNBC      heterozygote        6/2
                                                                                                          IP2-49      Non-TNBC       homozygote         4/0
                                                                                                            56          HER2        heterozygote       10/3
                                                                                                            83          HER2        heterozygote        6/7
  *BRCA1*       chr17:41246481      c.1067 T \> C    p.Q356R    1799950    missense          YES          IP2-42      Non-TNBC       homozygote         2/0
                                                                                                          IP2-49      Non-TNBC      heterozygote        4/7
                                                                                                          IP2-66      Non-TNBC      heterozygote        3/6
                chr17:41246061      c.1487 C \> T    p.R496H    28897677   missense          YES          IP2-71      Non-TNBC      heterozygote        4/4
                chr17:41245471      c.2077 C \> T    p.D693N    4986850    missense          YES            83          HER2         homozygote         4/1
                chr17:41246251       c.1156delG     p.A386Pfs   80357794    indel            YES          IP2-78        TNBC         homozygote         4/0
                chr17:41244936      c.2612 G \> A    p.P871E     799917    missense          NO           IP2-48      Non-TNBC      heterozygote        3/1
                                                                                                          IP2-49      Non-TNBC       homozygote         6/0
                                                                                                          IP2-66      Non-TNBC      heterozygote        6/3
                                                                                                            26          HER2         homozygote        20/0
                                                                                                            83          HER2        heterozygote        4/1
                                                                                                           171          HER2         homozygote         5/0
                                                                                                          IP2-78        TNBC        heterozygote        3/2
                chr17:41244435      c.3113 T \> C   p.E1038G    1799966    missense          NO           IP2-48      Non-TNBC       homozygote         2/0
                chr17:41244000      c.3548 T \> C   p.K1183R     16942     missense          NO           IP2-48      Non-TNBC       homozygote         3/0
                                                                                                            83          HER2        heterozygote        4/1
                                                                                                           171          HER2         homozygote         5/0
                chr17:41223094      c.4900 T \> C   p.S1634G    1799966    missense          NO           IP2-48      Non-TNBC       homozygote         3/0
                                                                                                          IP2-66      Non-TNBC       homozygote         4/0
                                                                                                           171          HER2         homozygote         4/0
  *BRCA2*       chr13:32906480      c.865 A \> C     p.N289H     766173    missense          YES            56          HER2        heterozygote        3/2
                chr13:32912750      c.4258 G \> T   p.D1420Y     766173    missense          YES            26          HER2        heterozygote        6/5
                chr13:32911463      c.2971 A \> G    p.N991D    1799944    missense          NO             56          HER2        heterozygote        4/4
                chr13:32929387      c.7397 T \> C   p.V2466A     169547    missense          NO           IP2-50        TNBC         homozygote         2/0
                                                                                                            26          HER2         homozygote         3/0
                                                                                                            56          HER2         homozygote         3/0
                                                                                                            83          HER2         homozygote         2/0
                                                                                                           171          HER2         homozygote         5/0
                chr13:32930673      c.7544 C \> T   p.T2515I    28897744   missense          NO           IP2-66      Non-TNBC       homozygote         2/0
  *STK11*       chr19:1220427       c.520 C \> T     p.H174Y       0       missense       YES/lung        IP2-42      Non-TNBC      heterozygote       8/18

###### Comparison between the observed prevalence of known SNPs in the 17 studied breast cancer samples and Exome Sequencing Project -- presented are the top 50 variants showing higher prevalence among the 17 samples. The variants are sorted according descending chi-square value. High Polyphen score indicates high probability of the variant to alter the protein function

              17 Breast cancer samples   ESP        Chi-Square Test   HapMap                                                                                                     
  ---------- -------------------------- ----- ---- ----------------- -------- ------- ------- ------- ------ --------- ------ -------- ------ ------ ------ ----------- -------- -------
  HOOK2                  3                6    28        0.21           8      12136   0.001   325.1   912       0      766      0       0      0     7.3     2305376     G10R    0.99
  ANTXR1                 3                3    31        0.10           21     12903   0.002   59.5    138       0       95      0       NA     NA     NA    28365986     R7K     0.009
  MCOLN1                 3                4    30        0.13           46     12960   0.004   37.6    115       0       88      0       NA     NA     NA    73003348    T261M    0.614
  C3orf17                3                4    30        0.13           65     12925   0.005   26.5     82       0       62      0       NA     NA     NA    115971253   V297I    0.117
  TNKS1BP1               5                6    28        0.21          182     12808   0.014   15.1     63       0       52      0       NA     NA     NA    34448143    A100P    0.194
  PLEC                   4                6    28        0.21          185     12391   0.015   14.4     59       0       49      0       NA     NA     NA     3135103    R569Q    0.993
  DDX18                  3                4    30        0.13           93     12913   0.007   18.5     56       0       42      0       NA     NA     NA    61755349    V371I    0.011
  AP1M2                  3                3    31        0.10           52     12238   0.004   22.8     54       0       37      0       NA     NA     NA    34276903     Y85C    0.998
  GEMIN4                 3                6    28        0.21          297     12201   0.024    8.8     33       0       27      0       NA     NA     NA    191778127   H873Q      0
  LY75                   5                8    26        0.31          658     12348   0.053    5.8     24       0       20      0       NA     NA     NA    35941588    T1393I   0.435
  TXNDC5                 4                5    29        0.17          289     10583   0.027    6.3    18.8   0.00001   14.4   0.0001    NA     NA     NA    183777097    P49S      0
  HIST1H1B               6                6    28        0.21          512     12494   0.041    5.2    16.7   0.00004   13.3   0.0003    0     7.5     0     34144478    A211T    0.404
  IMPACT                 8               11    23        0.48          1602    11404   0.140    3.4    12.5   0.0004    10.8   0.001    4.3    16.9   2.2     582234     D125E    0.001
  AKAP9                  7                9    25        0.36          1229    11777   0.104    3.4    11.4   0.0007    9.5    0.002    1.7     15    0.6    35759833    K2476R   0.001
  QRSL1                  3                5    29        0.17          456     12550   0.036    4.7    12.5   0.0004    9.4    0.002     0      5     5.6    34221917    N263S    0.593
  DSG2                   6                7    27        0.26          759     11175   0.068    3.8    11.5   0.0007    9.2    0.002     0     9.9    0.2     2230234    I293V    0.99
  HLA-DRB5               6               10    24        0.42          1288    10016   0.129    3.2    10.9    0.001    9.2    0.002     NA     NA     NA    112872773   V209L      0
  JRK                    4                5    29        0.17          459     12219   0.038    4.6    11.9   0.0006    8.9    0.002     NA     NA     NA    34288113     T30M    0.988
  LAPTM5                 11              14    20        0.70          2541    10465   0.243    2.9    10.1    0.001    8.8    0.003    2.5    25.8   7.2    35351292    R226K    0.002
  DDRGK1                 8               11    23        0.48          1762    11244   0.157    3.1    10.2    0.001    8.7    0.003     0     19.2    0       11591     A303T    0.004
  KIF20B                 7               12    22        0.55          2044    10952   0.187    2.9    9.8     0.001    8.4    0.004    2.5    26.9   37.9    1129777     A50G    0.918
  GLB1                   4                6    28        0.21          637     11695   0.054    3.9    10.7    0.001    8.3    0.004     NA     NA     NA    73826339    S401G    0.001
  WDR55                  5                7    27        0.26          873     12133   0.072    3.6    10.4    0.001    8.3    0.004     NA     NA     NA    35983033    Y235C    0.998
  THUMPD3                8               10    24        0.42          1564    11442   0.137    3.0    9.7     0.001    8.1    0.004    4.3    18.9   7.8     1129174    R459Q    0.056
  NLRP2                  8               14    20        0.70          2629    10377   0.253    2.8    9.2     0.002     8     0.005     NA     NA     NA    34804158    T529A      0
  XPO5                   4                6    28        0.21          645     11467   0.056    3.8    10.1    0.001    7.9    0.005     0     14.2    0     34324334    S241N    0.002
  RRS1                   3                4    30        0.13          374     12560   0.030    4.5    9.4     0.002    6.6     0.01     NA    4.1    20.4    3739336    R191L    0.999
  PLSCR1                 6                6    28        0.21          770     12236   0.063    3.4    8.3     0.004    6.4     0.01     0     8.3    3.1     343320     H262Y    0.945
  PTPN12                 10              12    22        0.55          2252    10754   0.209    2.6    7.6     0.005    6.4     0.01    19.7   11.3   29.8    3750050    T573A    0.001
  REV3L                  4                6    28        0.21          789     12215   0.065    3.3    7.9     0.004     6      0.01    3.8    4.1     0      458017     Y1156C   0.002
  ERBB2IP                7                9    25        0.36          1498    11506   0.130    2.8    7.4     0.006     6      0.01     0     17.8   8.1     3213837    S274L    0.024
  SHARPIN                4                4    30        0.13          401     12255   0.033    4.1    8.1     0.004    5.6     0.02     NA     NA     NA    34674752    P294S    0.447
  KIAA1755               10              19    15        1.27          4605    8401    0.548    2.3    6.2     0.01     5.4     0.02    10.8   47.5   38.8    3746471    R1045W   0.003
  SEC63                  3                4    30        0.13          427     12579   0.034    3.9    7.6     0.006    5.2     0.02     NA     NA     NA    17854547    V556I    0.203
  LAMC2                  4                6    28        0.21          848     12158   0.070    3.1    6.9     0.009    5.2     0.02     0     9.9    0.2    11586699    T124M    0.999
  ZNF880                 4                7    27        0.26          376     4190    0.090    2.9    6.7     0.009    5.2     0.02     NA     NA     NA      14048      V12M    0.999
  IGFBP7                 7                8    26        0.31          640     5676    0.113    2.7    6.6     0.01     5.2     0.02     NA     NA     NA    11573021     L11F    0.005
  PHF3                   3                3    31        0.10          255     12751   0.020    4.8    8.2     0.04     5.1     0.02     NA     NA     NA    34288820    V525I    0.972
  KIAA0232               3                4    30        0.13          395     11489   0.034    3.9    7.5     0.006    5.1     0.02     NA     NA     NA    116439703   P1138S   0.22
  PJA1                   7               11    23        0.48          1742    8821    0.197    2.4    6.2     0.01     5.1     0.02    12.5   24.6   12.5   11539157    E606D    0.992
  PRCP                   3                3    31        0.10          265     12741   0.021    4.7    7.8     0.005    4.8     0.03     NA     NA     NA     2228312    T465S    0.021
  MXRA5                  14              23    11        2.09          5006    5557    0.901    2.3    5.6     0.02     4.8     0.03     22    27.6   34.9    1974522    P1665S   0.689
  PARP14                 7                7    27        0.26          1022    10826   0.094    2.7    6.1     0.01     4.7     0.03     4     7.6    10.9   13093808    A561E    0.972
  EML4                   12              15    19        0.79          3414    9592    0.356    2.2    6.6     0.02     4.7     0.03    11.7   26.7   43.9   28651764    K398R    0.003
  ACOX1                  13              24    10        2.40          6616    6390    1.035    2.3    5.3     0.02     4.5     0.03    13.6   34.9    29     1135640    I312M    0.007
  SP110                  3                6    28        0.21          928     12078   0.077    2.8    5.6     0.01     4.16    0.04     0      9      4     11556887    A128V    0.999
  PPL                    12              20    14        1.43          5261    7733    0.680    2.1    4.7     0.03      4      0.05     0     47.5   30.4    2037912    Q1573E   0.994
  TBL2                   3                4    30        0.13          489     12517   0.039    3.4    5.9     0.01     3.9     0.05     NA    3.1     NA    35607697    V345I    0.969
  ZBTB45                 3                4    30        0.13          491     12511   0.039    3.4    5.9     0.01     3.9     0.05     NA     NA     NA    35430780    D293E      0
  TMEM106C               4                6    28        0.21          962     12044   0.080    2.7    5.1     0.02     3.8     0.05     0     11.2   40.4    2286025    S175F    0.985

###### Deleterious mutations identified among the 17 Breast Cancer Samples

  Gene          Sample ID   \# Samples    Function        Location       REF allele   Var allel    Change      Zygosity
  ------------ ----------- ------------ ------------- ----------------- ------------ ----------- ---------- --------------
  ABCA10           56           1        stop-gained   chr17:67149973        G            A       p.R1322X    homozygote
  C17orf77       IP2-76         2        stop-gained   chr17:72588806        C            A       p.C207X     homozygote
  C17orf77       IP2-71         2        stop-gained   chr17:72588806        C            A       p.C207X     homozygote
  C5orf20          56           1        stop-gained   chr5:134782450        T            A       p.R117X     homozygote
  CARM1          IP2-50         1        stop-gained   chr19:11019790        C            A       p.Y155X    heterozygote
  CCDC25         IP2-90         1        stop-gained    chr8:27610077        C            A        p.E66X     homozygote
  DCAF11         IP2-50         1        stop-gained   chr14:24592413        C            A       p.Y486X    heterozygote
  EFHA1          IP2-69         1        stop-gained   chr13:22077082        T            A       p.K306X    heterozygote
  EGFL6            171          1        stop-gained    chrX:13624542        C            T       p.R189X     homozygote
  ERV3-1         IP2-50         1        stop-gained    chr7:64452738        G            A       p.R223X     homozygote
  EXOC7,ZACN       56           4        stop-gained   chr17:74077797        C            T       p.Q281X    heterozygote
  EXOC7,ZACN     IP2-76         4        stop-gained   chr17:74077797        C            T       p.Q281X     homozygote
  EXOC7,ZACN     IP2-78         4        stop-gained   chr17:74077797        C            T       p.Q281X     homozygote
  EXOC7,ZACN       171          4        stop-gained   chr17:74077797        C            T       p.Q281X    heterozygote
  FCGR2A         IP2-65         1        stop-gained   chr1:161476204        C            T        p.Q62X     homozygote
  GAB4           IP2-90         1        stop-gained   chr22:17469049        C            A       p.G163X     homozygote
  GET4           IP2-83         1        stop-gained     chr7:931966         C            A       p.Y219X     homozygote
  HNRNPR         IP2-76         1        stop-gained    chr1:23637469        G            T       p.Y460X    heterozygote
  IL17RB         IP2-83         1        stop-gained    chr3:53899276        C            T       p.Q484X    heterozygote
  LAIR2          IP2-76         1        stop-gained   chr19:55019261        C            T        p.R76X    heterozygote
  LOC1009964       26           1        stop-gained    chr6:57398270        C            T       p.Q325X    heterozygote
  MAD2L1BP       IP2-49         1        stop-gained    chr6:43608124        C            T       p.R227X    heterozygote
  MADD           IP2-83         1        stop-gained   chr11:47306630        C            T       p.R766X     homozygote
  MAGEB16        IP2-66         1        stop-gained    chrX:35821127        C            T       p.R272X     homozygote
  METAP1         IP2-50         1        stop-gained    chr4:99982427        C            T       p.R374X    heterozygote
  MTA2           IP2-83         1        stop-gained   chr11:62364262        G            T       p.Y243X     homozygote
  NHLRC2         IP2-76         1        stop-gained   chr10:115618327       C            A        p.Y73X    heterozygote
  PDE4DIP          171          1        stop-gained   chr1:144915561        G            A       p.R622X    heterozygote
  PDE4DIP        IP2-65         1        stop-gained   chr1:145075683        C            T        p.W60X     homozygote
  PDE4DIP        IP2-49         2        stop-gained   chr1:144916676        C            T       p.W560X    heterozygote
  PDE4DIP          26           2        stop-gained   chr1:144916676        C            T       p.W560X    heterozygote
  PELI3          IP2-50         1        stop-gained   chr11:66235714        G            T        p.E39X     homozygote
  PKD1L2         IP2-65         1        stop-gained   chr16:81242198        G            A       p.Q220X     homozygote
  PRB4           IP2-49         1        stop-gained   chr12:11461802        G            A        p.R39X     homozygote
  PRM3           IP2-76         1        stop-gained   chr16:11367143        G            A       p.R104X     homozygote
  RHBDD3         IP2-49         1        stop-gained   chr22:29656431        C            T       p.W289X     homozygote
  SKIV2L         IP2-42         1        stop-gained    chr6:31936654        C            T       p.R1063X    homozygote
  SYNE2            26           1        stop-gained   chr14:64560092        G            A       p.W4001X    homozygote
  TMEM134        IP2-42         1        stop-gained   chr11:67235051        G            A        p.R84X    heterozygote
  VPS13B           171          1        stop-gained   chr8:100133706        T            G       p.Y413X     homozygote
  ZSWIM3           171          1        stop-gained   chr20:44505411        G            T        p.E72X     homozygote
  ANKS1A         IP2-69         1           INDEL       chr6:34738008        A           AA                   homozygote
  ANKS1A         IP2-42         1           INDEL       chr6:34902473        G           GT                  heterozygote
  CABIN1           171          1           INDEL      chr22:24455826        G          GAAAA                 homozygote
  CABIN1           83           1           INDEL      chr22:24448944        T           TT                   homozygote
  CANX           IP2-69         2           INDEL      chr5:179140762        A           AA                   homozygote
  CMYA5            56           1           INDEL       chr5:78982956       GCTT       GCTTCTT                homozygote
  EME1             56           1           INDEL      chr17:48276005        C           CC                   homozygote
  LAMA3          IP2-49         1           INDEL      chr18:21434967      ATAAA          A                   homozygote
  MGST2          IP2-42         3           INDEL      chr4:140619265        T           TT                   homozygote
  MRPS15           56           1           INDEL       chr1:36921785        TA        TGGAAAA                homozygote
  SLC17A5        IP2-78         1           INDEL       chr6:74351412        AC         ACACC                 homozygote
  SLC5A8         IP2-66         1           INDEL      chr12:101550975      CACA       CACACA                heterozygote
  SMARCA5          171          1           INDEL      chr4:144340520      AAGAA         AA                  heterozygote
  TRAPPC9        IP2-83         1           INDEL      chr8:141413543        A           AA                   homozygote
  ZNF100         IP2-50         1           INDEL      chr19:21908799       CACA         CA                   homozygote
  ZNFX1          IP2-42         1           INDEL      chr20:47871283    GACCCTTGGA                           homozygote

###### Novel Exonic Variants that are seen in two and three out of the 17 breast Cancer Samples

  Gene         Chromosomal Location    cDNA Annotation   Protein Annotation    Function    Samples   Cancer subtype
  ----------- ----------------------- ----------------- -------------------- ------------ --------- ----------------
  *SLC30A8*    chr8:118159203 C \> T     c.82 C \> T           p.Q28X         stop-codon   IP2-48       Non-TNBC
                                                                                           IP2-49       Non-TNBC
                                                                                           IP2-66       Non-TNBC
  *AGL*        chr1:100387140 G \> T    c.4484 G \> T         p.C1495F         missense    IP2-49       Non-TNBC
                                                                                           IP2-66       Non-TNBC
  *GLUD2*      chrX:120182480 A \> G    c.942 A \> G          p.L314L         synonymous   IP2-50         TNBC
                                                                                             83           TNBC
  *GPN1*       chr2:27873001 A \> G     c.1101 A \> G         p.E367E         synonymous   IP2-49       Non-TNBC
                                                                                           IP2-66       Non-TNBC
